Involved in many disease pathologies, DUBs are attractive therapeutic targets
World-leading DUB platform translating scientific advances into transformative therapies
First-in-class small molecule DUB inhibitors developed in-house and with partners
Multiple in-house USP30 DUB inhibitor programs approaching clinical development
Mission Therapeutics is determined to make a positive impact on the lives of patients suffering from serious diseases including acute kidney injury (AKI), rare mitochondria diseases, neurodegeneration, and fibrosis by developing first-in-class therapeutics that inhibit disease-associated deubiquitylating enzymes (DUBs).
To hear our CEO discuss our technology, programs, recent progress and strategy, watch our Corporate Presentation.
CAMBRIDGE, UK – 31 March 2022 – Mission Therapeutics (“Mission”),…